chufangao/CTO huggingface dataset:
Clinical trial NCT02890784: Dasatinib Holiday for Improved Tolerability
Official title: Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)
Acronym: DasaHIT
Sponsor: University of Jena (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 291.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT03976050: Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Official title: A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 in Subjects With Advanced Solid Tumors
Sponsor: Shanghai Kechow Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study objective and design change
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-17
Primary completion date: 2020-11-12
Completion date: 2020-11-12
Clinical trial NCT03767829: A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Official title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT02 in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided not to proceed with Part B for business reasons.
Enrollment: 32.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-05
Primary completion date: 2020-06-25
Completion date: 2020-06-25
Clinical trial NCT04834908: Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
Official title: A Prospective Randomized Multi-center Open Label Phase 1/2 Study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2](BSVEQAb) Plus Standard of Care in Comparison to Standard of Care Alone in COVID-19 RT-PCR Positive Patients
Acronym: PROTECT
Sponsor: Bharat Serums and Vaccines Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Closed as no eligible patient.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-27
Primary completion date: 2022-05-25
Completion date: 2022-05-25
Plan to share individual participant data: NO
Clinical trial NCT03323398: Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Official title: A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies
Sponsor: ModernaTX, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-15
Primary completion date: 2021-08-18
Completion date: 2021-08-18
Baseline population: Safety Set included all enrolled participants who received any amount of study drug. Participants were included in the dose cohort corresponding to the dose level they actually received. No baseline characteristics data is reported for Arm A, Dose Confirmation: mRNA-2416 8.0 mg Alone or Arm B, Dose Expansion: mRNA-2416 2.0 mg and Durvalumab to maintain participant confidentiality.
Limitations and caveats: This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.
Plan to share individual participant data: NO
Clinical trial NCT03585725: A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
Official title: A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-26
Primary completion date: 2020-07-22
Completion date: 2020-07-22
Plan to share individual participant data: NO
Clinical trial NCT03978611: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
Official title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-09
Primary completion date: 2023-07-26
Completion date: 2023-07-26
Clinical trial NCT03474263: IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Official title: A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With
Sponsor: Implicit Bioscience (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: seeking research grant support
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-01
Primary completion date: 2021-04-12
Completion date: 2021-07-12
Plan to share individual participant data: NO
Clinical trial NCT04717557: Hyperbaric Oxygen and Outcome After Below Knee Amputations
Official title: Hyperbaric Oxygen Therapy to Prevent Complications After Lower Limb Amputation
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-01
Primary completion date: 2023-07-31
Completion date: 2023-10-31
Plan to share individual participant data: NO
Clinical trial NCT02644252: Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
Official title: Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Acronym: Toco-Pulm
Sponsor: Vejle Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The trial was ended prematurely because of a poor accrual rate
Enrollment: 79.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-01-31
Primary completion date: 2019-05-09
Completion date: 2021-01-15
Clinical trial NCT03845270: Her2-positive Lung Cancer Treated With Dedicated Drug
Official title: Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel
Acronym: R2D2
Sponsor: Intergroupe Francophone de Cancerologie Thoracique (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-17
Primary completion date: 2021-02-01
Completion date: 2023-12-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05175131: Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
Official title: Multicenter, Randomized, Parallel-group, Open-label, Comparative Clinical Study to Evaluate Efficacy and Safety of Mebeverine+Simethicone Fixed-dose Combination Versus Duspatalin® (Mebeverine) and Versus Espumisan® (Simethicone) in Patients With Functional Bowel Disorders With Abdominal Pain and Excess Gas Formation
Sponsor: Abbott (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 465.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-27
Primary completion date: 2021-05-18
Completion date: 2021-05-18
Plan to share individual participant data: NO
Clinical trial NCT03818672: Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
Official title: Open Label Study to Evaluate the Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy Subjects and Subjects With Severe Hepatic Impairment
Sponsor: Bausch Health Americas, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study determined to be infeasible.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-29
Primary completion date: 2020-02-02
Completion date: 2020-02-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02970500: Effect of Methylphenidate on Cancer-related Cognitive Impairment
Official title: Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein
Acronym: CogMet
Sponsor: CHU de Quebec-Universite Laval (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: We decided to close recruitment in December 2022 as we were having trouble recruiting participants who met our inclusion criteria and the study funding was coming to an end.
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-09
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03367403: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
Official title: Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-18
Primary completion date: 2020-12-04
Completion date: 2021-09-21
Baseline population: All randomized participants.
Limitations and caveats: As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline. Clinical efficacy was not reported for this group.
Plan to share individual participant data: YES
IPD sharing description: Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Clinical trial NCT04396834: Mechanisms of Lorcaserin for Smoking Cessation
Official title: Behavioral Mechanisms of Lorcaserin Treatment for Smoking Cessation
Sponsor: The Mind Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Medication removed from the U.S. market by the The Food and Drug Administration
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-04
Primary completion date: 2020-02-26
Completion date: 2020-02-26
Baseline population: The trial was halted after randomizing the first two participants. Outcomes were not analyzed due to recruitment of only two participants.
Plan to share individual participant data: NO
Clinical trial NCT03904108: Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Official title: Phase-II Trial of Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: insufficient patient population to complete trial as planned
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-27
Primary completion date: 2020-07-27
Completion date: 2020-07-27
Plan to share individual participant data: NO
Clinical trial NCT03022097: Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
Official title: A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
Acronym: AVANT
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1067.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-01-24
Primary completion date: 2022-04-14
Completion date: 2022-04-14
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05510843: A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria
Official title: An Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effects of THB001 in Adult Patients With Chronic Cold Urticaria
Sponsor: Third Harmonic Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The decision to discontinue the study was made after observing moderate drug induced liver injury in two subjects enrolled in the first dose cohort.
Enrollment: 5.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-06
Primary completion date: 2023-03-30
Completion date: 2023-04-04
Plan to share individual participant data: YES
IPD sharing description: Results of safety (AEs, SAEs) will be made available.
IPD time frame: Within 1 year after last subject last visit.
Clinical trial NCT04313881: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Official title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
Acronym: ENHANCE
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study discontinued due to futility based on a planned analysis
Enrollment: 539.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-09
Primary completion date: 2023-09-13
Completion date: 2023-09-13
Baseline population: The Intent-to-treat (ITT) Analysis Set included all participants who were randomized in the study, with treatment assignments designated according to the treatment that participants were randomized to.
Plan to share individual participant data: NO
Clinical trial NCT03797066: ATTIC - Access To Treat in the Community
Official title: Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Participants With Genotype 1a, 1b or 4 to Measure Efficacy and Adherence to Treatment in a Homeless Population
Acronym: ATTIC
Sponsor: King's College Hospital NHS Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Changing parameters in HCV management, resulted in poor recruitment; additionally onset of SARS CoV2 resulted in the cessation of all mobile clinical services.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-23
Primary completion date: 2020-07-28
Completion date: 2020-11-30
Plan to share individual participant data: NO
IPD sharing description: anonymised data sharing only, via publications
Clinical trial NCT02384954: QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Official title: A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Sponsor: Altor BioScience (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Change in drug product development strategy.
Enrollment: 43.0 (ACTUAL)
Number of arms: 9.0
Start date: 2015-04-17
Primary completion date: 2020-12-13
Completion date: 2020-12-13
Clinical trial NCT03759639: N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
Official title: Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Sponsor: IntraBio Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-04
Primary completion date: 2022-11-07
Completion date: 2022-11-07
Limitations and caveats: This study was ongoing during the coronavirus disease 2019 (COVID-19) pandemic, and the conduct of this study was impacted by the COVID-19 pandemic.
Clinical trial NCT04079231: Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Official title: A Comparative Double Masked, Two-Arm, Randomized, Multicenter, Phase IIIb Study Analyzing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)
Acronym: BUZZARD
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: This study was cancelled due to COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on ww.clinicalstudydatarequest.com.
Clinical trial NCT03635099: This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
Official title: Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 274.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-09-17
Primary completion date: 2021-05-06
Completion date: 2021-05-26
Baseline population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI).
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT05403580: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Official title: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patients - A Confirmatory Phase III MNCCTN Trial
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Closed due to slow accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-03
Primary completion date: 2023-12-29
Completion date: 2024-12-31
Clinical trial NCT03819153: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Official title: Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Acronym: FLOW
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 3508.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-17
Primary completion date: 2024-01-09
Completion date: 2024-01-09
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT03586024: Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Official title: Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: poor accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-12
Primary completion date: 2020-08-19
Completion date: 2020-08-19
Plan to share individual participant data: NO
Clinical trial NCT04477642: Abatacept for Patients With COVID-19 and Respiratory Distress
Official title: Abatacept for Patients With COVID-19 and Respiratory Distress
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-31
Primary completion date: 2020-10-31
Completion date: 2020-12-31